Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

13.96
-0.0500-0.36%
Post-market: 14.160.2019+1.45%17:04 EDT
Volume:1.58M
Turnover:21.87M
Market Cap:993.81M
PE:-16.11
High:14.23
Open:14.00
Low:13.42
Close:14.01
52wk High:15.10
52wk Low:1.94
Shares:71.19M
Float Shares:58.79M
Volume Ratio:1.19
T/O Rate:2.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8667
EPS(LYR):-0.8930
ROE:-34.18%
ROA:-20.52%
PB:4.34
PE(LYR):-15.63

Loading ...

Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis

Reuters
·
May 15

3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%

Simply Wall St.
·
May 13

Immix Biopharma posts corporate presentation on NXC-201 CAR-T for relapsed AL amyloidosis

Reuters
·
May 13

Immix Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Immix Biopharma Q1 net loss widens to USD 10.09 million

Reuters
·
May 08

Immix Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
May 05

Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis

Reuters
·
May 05

Immix Biopharma publishes corporate presentation on NXC-201 CAR-T in relapsed AL amyloidosis

Reuters
·
May 03

Immix Biopharma to participate in Jefferies Global Healthcare Conference, hosts investor meetings

Reuters
·
Apr 09

Immix Biopharma announces annual shareholder meeting

Reuters
·
Apr 07

Infinimmune: Under Agreement, Merck Will Have Exclusive Right to Develop and Commercialize Antibody Candidates

THOMSON REUTERS
·
Mar 31

Immix Biopharma Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 31

Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon

TIPRANKS
·
Mar 30

Immix Biopharma completes enrollment in NEXICART-2 AL amyloidosis BLA-enabling trial

Reuters
·
Mar 30

Immix Biopharma Announces Enrollment Completion of Bla-Enabling Relapsed/Refractory Al Amyloidosis Trial Nexicart-2, and Upcoming Milestones

THOMSON REUTERS
·
Mar 30

Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 27

Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $15 From $12

THOMSON REUTERS
·
Mar 27

U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings

Reuters
·
Mar 27

Immix Biopharma, Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 26

Immix Biopharma Q4 EPS $(0.28) Misses $(0.16) Estimate

Benzinga Earnings
·
Mar 26